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Background: There is increasing interest in balanced propofol sedation (BPS) titrated to moderate sedation
(conscious sedation) for endoscopic procedures. However, few controlled studies on BPS targeted to deep sedation
for diagnostic endoscopy were found. Alfentanil, a rapid and short-acting synthetic analog of fentanyl, appears to
offer clinically significant advantages over fentanyl during outpatient anesthesia.
It is reasonable to hypothesize that low dose of alfentanil used in BPS might also result in more rapid recovery as
compared with fentanyl.
Methods: A prospective, randomized and double-blinded clinical trial of alfentanil, midazolam and propofol versus
fentanyl, midazolam and propofol in 272 outpatients undergoing diagnostic esophagogastroduodenal endoscopy
(EGD) and colonoscopy for health examination were enrolled. Randomization was achieved by using the
computer-generated random sequence. Each combination regimen was titrated to deep sedation. The recovery
time, patient satisfaction, safety and the efficacy and cost benefit between groups were compared.
Results: 260 participants were analyzed, 129 in alfentanil group and 131 in fentanyl group. There is no significant
difference in sex, age, body weight, BMI and ASA distribution between two groups. Also, there is no significant
difference in recovery time, satisfaction score from patients, propofol consumption, awake time from sedation, and
sedation-related cardiopulmonary complications between two groups. Though deep sedation was targeted, all
cardiopulmonary complications were minor and transient (10.8%, 28/260). No serious adverse events including the
use of flumazenil, assisted ventilation, permanent injury or death, and temporary or permanent interruption of
procedure were found in both groups. However, fentanyl is New Taiwan Dollar (NT$) 103 (approximate US$ 4)
cheaper than alfentanil, leading to a significant difference in total cost between two groups.
Conclusions: This randomized, double-blinded clinical trial showed that there is no significant difference in the
recovery time, satisfaction score from patients, propofol consumption, awake time from sedation, and
sedation-related cardiopulmonary complications between the two most common sedation regimens for EGD and
colonoscopy in our hospital. However, fentanyl is NT$103 (US$ 4) cheaper than alfentanil in each case.
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Esophagogastroduodenal endoscopy (EGD) and colonos-
copy are among the most widely utilized procedures
worldwide that are performed with intravenous sedation,
so effective sedation with prompt recovery is important.
There is increasing interest in balanced propofol sed-
ation (BPS) titrated to moderate sedation (conscious sed-
ation) for endoscopic procedures [1-6].
BPS combines propofol with small doses of an opioid
and a benzodiazepine. A positive synergistic interaction
is noted among these drugs. Therefore, each drug’s
therapeutic action is enhanced while the adverse effects
of each are minimized because of the small doses used.
Compare with conventional sedation (a combination
of a benzodiazepine and an opioid e.g. midazolam and
meperidine), BPS can be used safely and effectively for
diagnostic and therapeutic endoscopy and provides
higher health care provider satisfaction and better pa-
tient cooperation.
Midazolam, fentanyl and alfentanil are the most pre-
ferred sedo-analgesics with short acting effects on γ-
aminobutyric acid and μ-opiate receptors, which provide
a rapid induction and recovery with minimal residual
side effects for endoscopy [7,8].
Alfentanil, a rapid and short-acting synthetic analog of
fentanyl, appears to offer some clinically significant
advantages over fentanyl during outpatient anesthesia [9].
Alfentanil was also used as an adjuvant to midazolam
for sedation of outpatients undergoing upper gastro-
intestinal endoscopy. The use of alfentanil resulted in
improved operating conditions and a more rapid recov-
ery as compared with patients sedated with midazolam
alone. Patient acceptance was also higher [10].
Moreover, with its rapid recovery effect, alfentanil is
superior to fentanyl in patient- controlled analgesia and
sedation for colonoscopy [11].
Therefore, it is reasonable to hypothesize that low
dose of alfentanil used in BPS might also be result in
more rapid recovery as compared with fentanyl. How-
ever, there are few controlled studies with direct com-
parison between alfentanil and fentanyl in BPS.
In addition, deep sedation rather than moderate sed-
ation for endoscopy was preferred by most of the
patients undergoing diagnostic colonoscopy for health
check-up in Taiwan [12,13].
Thus, we design this prospective, randomized, and
double blind clinical trial to compare the effectiveness,the recovery and the safety profiles between small dose
of alfentanil and fentanyl adjunct to BPS targeted to
deep sedation for patients undergoing diagnostic EGD
and colonoscopy for health examination. Cost benefit
analysis between alfentanil and fentanyl might also be
performed.Methods
Patient selection and study design
This was a single-center, prospective, randomized, and
double-blinded study of 260 consecutive patients under-
going diagnostic EGD and colonoscopy for health exam-
ination between July 2008 and June 2009. The study was
conducted according to the Declaration of Helsinki and
was approved by the Institutional Review Board of Tzu
Chi General Hospital. Verbal and written informed con-
sent for this study was obtained from each patient.
Clinical criteria for patient exclusion from BPS
included patients of age less than 20 years; pregnancy;
American Society of Anesthesiology (ASA) physical sta-
tus class IV; history of allergies to propofol, soybeans, or
eggs; chronic lung disease; history of drug or alcohol
abuse; history of seizure disorder, sleep apnea, or diffi-
cult intubation; a short, thick neck or inability to open
the mouth widely; history of complications with previous
sedation and inability to provide informed consent.
A total of 272 patients were invited to participate. No
patient was excluded for any of the exclusion criteria
and all the screened patients consented to randomi-
zation. However, 12 patients were excluded eventually
due to poor bowel preparation (7 in alfentanil group and
5 in fentanyl group). Thus, 260 patients completed the
study (Figure 1).
All endoscopic procedures were performed by an
experienced endoscopist who was faculty at the hospital.
Patients were randomly assigned to 1 of 2 sedation pro-
tocols (alfentanil group [propofol in combination with
midazolam and alfentanil] vs fentanyl group [propofol
in combination with midazolam and fentanyl]) by using
a computer-generated random sequence. Both random-
ization and the opioids used for analgesia were con-
cealed from all patients, anesthesiologist, endoscopist,
endoscopy nurses, recovery-room nurses, and an inde-
pendent research nurse who responded for recovery
evaluation in post-anesthesia room and 24-hour tele-
phone follow-up survey.
Assessed for eligibility 
 (n=272) 
Excluded (n=0)
Not meeting inclusion criteria (n=0) 
Declined to participate (n=0) 
Other reasons (n=0) 
Analysed (n=129) 
Poor Bowel Preparation 
(n=7) 
Alfentanil group 
(Midazolam + Alfentanil + Propofol) 
(n=136) 
Poor Bowel Preparation 
(n=5) 
Fentanyl group 




Figure 1 Flow diagram of the study.
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All sedatives and analgesics used for this study were
administered by only one anesthesiologist. The opioid
and midazolam were given by intravenous bolus injection
at the initiation of sedation. All the patients received mid-
azolam 2.5 mg, and in combined with alfentanil 0.25 mg
(RapifenW 1 mg/2 ml; Janssen-Cilag Limited, Belgium) for
the alfentanil- propofol group or fentanyl 0.025 mg
(Fentanyl-Fresenius 0.1 mg/2 ml; Bodene (Pty) Limited,
South Africa) for the fentanyl-propofol group.
Thereafter, an initial bolus of propofol (0.5 mg/kg body
weight) was given intravenously. Sedation was main-
tained with repeated doses of 10 to 20 mg propofol. The
goal of sedation was deep sedation, based on ASA levels
and the Observer's Assessment of Alertness/Sedation
scale (OAAS scale) [14,15], which defines as a patient
who responds purposely to a painful stimulus (e.g. tra-
pezius squeeze) but fails to response to verbal or light
tactile stimuli.
The gastroscopy was performed first and followed with
colonoscopy. Repeated dose of alfentanil or fentanyl was
administered just before the start of colonoscopy. There-
fore, each patient’s total dose of alfentanil or fentanyl was
0.5 mg and 0.05 mg, respectively. During the insertion of
the colonoscopy, deep sedation was also maintained with
10 to 20 mg increments of propofol. Usually no more
propofol was added during the withdrawal phase.
All EGD and colonoscopy examinations in this study
were performed by one experienced gastroenterologistusing a standard video gastroscope (EG-590WR; Fujinon
Corp., Saitama, Japan) and colonoscope (EC-450WL5;
Fujinon Corp).
Blinding was achieved by having an independent re-
search nurse, according to a grid known only to her, pro-
vided each patient a 1 ml tuberculin syringe containing
either alfentanil 0.5 mg/ml or fentanyl 0.05 mg/ml.
Since the alfentanil and fentanyl were clear and color-
less aqueous solutions, they were unable to be identified.
Therefore, the anesthesiologist, gastroenterologist, nurses
and patients were all blinded to treatment randomization.
Patient monitoring
The baseline vital signs were recorded just before the
procedure. Both preoxygenation with intranasal supple-
mental oxygen (6 L/min) and normal saline solution
were provided to all patients at the initiation of the pro-
cedure. All patients were continuously monitored for
heart rate, blood pressure, blood oxygen saturation
(SpO2) by using an automated device (Datascope 3000;
Datascope Corp., Montvale, N.J.) until full recovery. Re-
spiratory effort, respiratory rate, and chest wall excur-
sion were monitored by visual inspection and palpation.
The anesthesiologist recorded all the monitoring para-
meters, total procedure time from the continuously run-
ning stopwatch and undertook chin lift, safety end
points and advanced life-support.
Equipment for full resuscitation was available at all
times within the endoscopy unit. Both flumazenil and
Ho et al. BMC Gastroenterology 2012, 12:164 Page 4 of 10
http://www.biomedcentral.com/1471-230X/12/164naloxone could be used as reversal agents when severe
adverse effects associated with the use of midazolam and
opioids were suspected.
Outcome measurements and definitions
The primary outcomes were to compare the recovery
time and the procedure-related times (awake and total
procedure times) between the two groups. Awake time
was defined as the time interval between “colonoscope
removal” and “patient reaching OAAS scale 5” which
means that the patient responds appropriately to normal
volume verbal cues by using either a verbal or physical
response without delay or hesitation.
Total procedure time was defined as the time interval
between “start of gastroscopy” and “colonoscope re-
moval”. Recovery time was defined as the time interval
between “colonoscope removal” and “discharge from the
endoscopy unit”. If there was transient interruption of
the procedure due to sedation-related adverse events,
that time was subtracted from the total procedure time.
Secondary outcomes included the total amount of pro-
pofol used and the incidences of cardiopulmonary com-
plications between the two groups. Cardiopulmonary
complications included [1] systolic hypotension (systolic
blood pressure < 90 mm Hg), [2] bradycardia (heart rate
< 50 beats/min), [3] hypoxemia (pulse oximeter oxygen
saturation (SpO2) < 90% on supplemental oxygen), and
[4] permanent injury or death. If the SpO2 dropped to
< 90% for >15 seconds, the patient’s chin was lifted. If
the SpO2 dropped to < 85% for > 30 seconds, assisted
ventilation was applied and an antagonist to midazolam
(flumazenil) could be injected. The procedure was inter-
rupted until normalization of the oxygen saturation.
Transient interruption of the procedure was defined as
procedure interruption due to sedation’s adverse events
for > 30 seconds.
Discharge evaluation and 24-hour follow-up
Upon completion of the EGD and colonoscopy proced-
ure, patients were taken directly to the recovery area,
where an initial set of pulse, blood pressure and pulse
oximetry was taken immediately. An independent
blinded research nurse determined the earliest time at
which patients were judged to be fully alert, and time
they were able to stand unassisted by the bed without
hypotension (systolic blood pressure < 100 mmHg) or
hypoxia (SpO2 <95% by pulse oximetry). When these
points were reached, the patient was considered ready
for discharge.
Before discharge, modified from Sipe et al. [15] and
Cohn et al. [2], the patient was asked to fill out a short
questionnaire using standard 10-cm visual analog scales
to report the amount of pain they experienced during
the procedure and overall satisfaction with theprocedure. The patient was asked verbally whether they
remembered being awake during the procedure.
Patients also were follow-up by phone 24 hours later
and a follow-up questionnaire was completed (Appendix).
Cost benefit analysis
Individual patient's anesthetic costs, including only seda-
tive and analgesic consumed, would be calculated and
analyzed between the groups.
Statistical analysis
The t test was used for continuous data. The Chi square
test or Fisher exact test was used for comparison of cat-
egorical data when appropriate. A P value of less than
0.05 was considered to be statistically significant. All
data were analyzed by using the Statistical Package for
the Social Sciences software, version 15.0 for Windows.
Calculation of sample size was based on the primary
objective of the study, i.e., the recovery time of each
sedation regimen. Based on our pilot study, the aver-
age recovery time of fentanyl sedation regimen was
15 minutes. We assumed that the difference of recovery
times was around 2.5 to 3 minutes between the groups.
Assuming a 10% dropout rate, 136 patients were needed
in each group with an alpha value of .05 and a power of
80% [16].
Results
Study population and baseline characteristics
There were 272 patients, who were eligible for inclusion
in the study, of whom 12 were excluded (7 in alfentanil
group and 5 in fentanyl group) for poor bowel pre-
paration. A total of 260 patients who had a complete
examination were considered in the results of the study,
133 male and 127 female. The baseline characteristics
of patients were exactly the same in the two groups
(Table 1). About 93.4% of the patients (243/260) were
classified as ASA class I or II.
Mean total dose of drugs used, total anesthetic cost and
procedure- related times
A summary of the mean total dose of sedatives and
analgesics administered, total anesthetic cost and the
mean procedure-related times are presented in Table 2.
No statistically difference was found in any parameter
except the total anesthetic cost.
The wholesale prices of alfentanil (2 cc ampoule, 0.5 mg/
ml) and fentanyl (2 cc ampoule, 0.05 mg/ml) are NT$225
and NT$20, respectively. Each 2 cc ampoule of alfentanil or
fentanyl was subdivided for two patients. Therefore, alfenta-
nil 0.5 mg and fentanyl 0.05 mg charged NT$ 113 and NT
$10, respectively. Thus, the cost difference was about NT
$103, being approximately US$ 4 and leading to a signifi-
cant difference between the groups.
Table 1 Basic characteristics of the study groups
Characteristic Alfentanil group (n=129) Fentanyl group (n=131) P value
Age, mean±SD (range), y 53.54±10.30 (27–85) 52.34±11.55 (29–87) 0.378
Male/Female 66/63 67/64 1.000
Body weight, mean (SD), kg 62.57 (11.03) 61.55 (11.69) 0.362
BMI, mean (SD), kg/m2 23.86 (3.42) 24.00 (3.75) 0.507
ASA classification, n (%) 1.000
I 39 (30.2) 40 (30.5)
II 82 (63.6) 82 (62.6)
III 8 (6.2) 9 (6.9)
IV 0 0
Baseline SBP, mean (SD), mm Hg 118.26 (14.27) 121.79 (16.84) 0.070
Baseline DBP, mean (SD), mm Hg 76.11 (10.92) 76.95 (12.83) 0.568
Baseline MAP, mean (SD), mm Hg 89.26 (11.22) 90.98 (13.25) 0.260
Baseline HR, mean (SD), beats/min 71.36 (11.34) 72.65 (11.84) 0.372
Baseline SpO2, mean (SD), % 97.76 (1.02) 97.74 (0.99) 0.874
ASA, American Society of Anesthesiologists; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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The overall rate of cardiopulmonary adverse events was
10.9% (14/129) in the alfentanil group and 10.7% (14/
131) in the fentanyl group (Table 3). However, there was
no significant difference between the 2 groups
(P=0.966). All complications were successfully managed
with conservative care.
Systolic hypotension was the most frequently reported
adverse event in both groups (9.3% [12/129] in the alfen-
tanil group vs 8.4% [11/131] in the fentanyl group;
P=0.797). Among these systolic hypotension patients,
mean arterial pressure decreased more than 25% of their
baseline was 3.1% [4/129] in the alfentanil group vs 1.5%
[2/131] in the fentanyl group (P=0.445).
Hypotension was corrected by increasing saline infu-
sion rate and only one patient needed small dose of
vasopressor (ephedrine 5 mg IV).Table 2 Sedative analgesic doses, cost and procedure-related
Alfentanil group (n=129)





Total anesthetic cost, mean±SD (range), NT$
154.00±9.34 (126–183)
Procedure-related times, mean±SD (range), min
Total procedure time 14.97±4.20 (8.10-30.36)
Awake time 6.35±3.01 (1.10-19.05 )
Recovery time 13.67±4.52 (5.45-30.65)Hypoxemia was the second common adverse event in
both groups (3.1% [4/129] in the alfentanil group vs
2.3% [3/131] in the fentanyl group; P=0.721). All patients
with hypoxemia required chin lift support only and no
assisted ventilation was needed.
One case of bradycardia was noted in fentanyl group
and treated with atropine sulfate 0.5 mg. No serious ad-
verse events including the use of flumazenil, permanent
injury or death, and temporary or permanent interrup-
tion of procedure were found in both groups.Patient assessment and satisfaction with sedation
Patient’s sensation of the endoscopic experience is
shown in Table 4.
The immediate post-procedure questionnaire (e.g. pain
during the procedure (VAS score), the overall satisfactiontimes






6.31±2.78 ( 0.82-16.80) 0.899
13.38±3.86 (6.07-28.57) 0.101






Cardiopulmonary complications 14 (10.9) 14 (10.7) 0.966
Systolic hypotension (<90mmHg) 12 (9.3) 11 (8.4) 0.797
MAP decreased >25% 4 (3.1) 2 (1.5) 0.445
Use of vasopressors 1 (0.8) 2 (1.5) 0.445
Bradycardia (<50 beats/min) 0 0 0.445
Hypoxemia (SpO2 < 90%) 4 (3.1) 3 (2.3) 0.721
Chin lift 4 (3.1) 1 (0.8) 0.212
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the procedure) were completed by all patients, 129 and
131 patients in alfentanil and fentanyl group, respect-
ively. No difference was found between the groups. The
VAS pain score during the procedure was minimal,
0.22±0.61 in the alfentanil group vs 0.17±0.53 in the
fentanyl group, (P=0.489). Also, the overall satisfaction
with the procedure (VAS score) was high, 9.43±0.63 in
the alfentanil group vs 9.49±0.57 in the fentanyl group,
(P=0.469). The incidence of being awake during the pro-
cedure was low, only 0.8% in the alfentanil group vs 1.5%
in the fentanyl group, (P=1).
The survey conducted 24 hours after discharge was
also completed by all patients. Similarly, there was no
statistically difference between the groups. The overall
satisfaction with the sedation was high. 83.7 percent of
patients described it as “excellent” and 16.3% rated it
“good” in the alfentanil group vs 83.2% described it as
“excellent” and 16.8% rated it “good” in the fentanyl
group, (P=0.911).
Most patients’ normal activities of the rest of the day
were not impaired by the sedation, 96.9% in the alfenta-
nil group vs 96.2% in the fentanyl group, (P=1). The ma-
jority of the patients did not require additional sleep
after discharge from the endoscopy unit, 94.6% in the
alfentanil group vs 96.9% in the fentanyl group,
(P=0.374). Few slept for periods of time that ranged
from 1 to 4 hours, 2.29±1.07 hour in the alfentanil group
vs 3.00±1.15 hour in the fentanyl group, (P=0.351).
Discussion
This study is the first randomized, double blind con-
trolled trial to compare the efficacy and the safety of
small dose alfentanil and fentanyl in BPS titrated to deep
sedation for health examination patients undergoing
diagnostic endoscopy. Though alfentanil is the preferred
narcotic due to its shorter duration and fewer side
effects compared with fentanyl; in the present study,
there were no differences in the recovery, awake and
total procedure times between the groups.
Small doses of alfentanil (incremental dose 0.25 mg,
total 0.5 mg) and fentanyl (incremental dose 0.025 mg,total 0.05 mg), were used in the present study might be
the main reason.
From Coda’s opinion, fentanyl administrated as a sin-
gle intravenous dose for short surgical procedure in
adults developed as a short-acting opioid and incremen-
tal doses of 0.025 to 0.05 mg are recommended [17].
Similarly, the recommended bolus doses of alfentanil
are 0.25 to 0.5 mg.
In Usta’s study [11], patient controlled analgesia and
sedation with alfentanil or fentanyl combined with mida-
zolam for colonoscopy showed that total sedation times
were shorter in the alfentanil group compared with the
fentanyl group. The mean dose of alfentanil and fentanyl
were 1 mg and 0.08 mg respectively, which was larger
than the present study.
In an earlier study, Holloway et al. [18] showed that
patients undergoing conscious sedation for colonoscopy
with midazolam and alfentanil had better operating
conditions compared with midazolam and fentanyl, but
the recovery time was similar. The mean doses of alfen-
tanil and fentanyl were low, 0.541 mg and 0.064 mg
respectively.
Our narcotic doses and the comparison of recovery
time are similar to Holloway's study. It suggests that
small dose of narcotics may not influence the recovery
time in BPS. Further study with the moderate dose in
this issue is warranted.
Small dose of midazolam 2.5 mg (average 0.04 mg/kg)
was chosen in the present randomized study. Hayee
et al. [19] reported a linear relationship between recov-
ery time and midazolam dose. At lower doses of midazo-
lam (2–3.5 mg), in combination with fentanyl for
colonoscopy, mean recovery time was significantly
shorter than at higher doses (4-5 mg). The slow metabo-
lization of benzodiazepines could prolong the recovery
time, reducing the turnover rate and efficiency of an
endoscopic unit. The mean recovery time in the present
study was around 15 min which was similar to VanNat-
ta’s study [3]. They showed that their mean recovery
time (the time from the end of the procedure to patient
discharge) was around 15 minutes for the BPS group tar-
geted to moderate sedation for colonoscopy. However,






Discharge for home 0.489
How much pain during the procedure, mean(SD), VAS
0.22 (0.61) 0.17 (0.53)
How was the overall satisfaction with the procedure, mean(SD), VAS, 0.469
9.43 (0.63) 9.49 (0.57)
Do you remember being awake during the procedure? n (%) 1.000
Yes 1 (0.8) 2 (1.5)
No 128 (99.2) 129 (98.5)
24 hours after procedure
On a scale of 1–10, how would you rate your procedure? mean(SD) 0.368
9.76 (0.57) 9.69 (0.59)
How was the sedation for your procedure? n (%) 0.911
Excellent 108 (83.7) 109 (83.2)
Good 21 (16.3) 22 (16.8)
Fair 0 0
Poor 0 0
Do you think you needed any adjustment of your sedation? n (%) 0.245
Needed more 1 (0.8) 0
Just right 127 (98.4) 131 (100)
Needed less 1 (0.8) 0
Do you remember the start of the procedure? n (%) 0.445
Yes 4 (3.1) 2 (1.5)
No 125 (96.9) 129 (98.5)
Do you think that the rest of the day was impaired by the sedation? n (%) 1.000
None 125 (96.9) 126 (96.2)
Mild 4 (3.1) 5 (3.8)
Moderate 0 0
Severe 0 0
Did you require additional sleep during the daytime after the procedure? n (%) 0.374
No 122 (94.6) 127 (96.9)
Yes 7 (5.4) 4 (3.1)
Time, mean±SD (range), hour 2.29±1.07 =(1-4) 3.00±1.15 (2-4) 0.351
Ho et al. BMC Gastroenterology 2012, 12:164 Page 7 of 10
http://www.biomedcentral.com/1471-230X/12/164their midazolam dose was only 1.0 mg and might add
advantages to recovery time. Therefore, reduced the
midazolam dose in our study might further decrease the
recovery time. However, we did not test that hypothesis
in this study.
Both types of BPS seem to be equally safe in the
present study.
Though deep sedation was targeted, all cardiopulmon-
ary complications were minor and transient. No patient
required assisted ventilation or had neurological injury
or death. The reasons for the favorable safety profile of
this study are as follows. First, it allows precise titrationof propofol, with a smaller bolus of doses to maintain an
acceptable status of deep sedation. Second, it is clear
that a synergistic effect of propofol with benzodiazepines
and opioids can reduce the total dose of propofol, thus
reducing the severity of cardiopulmonary complications
[1-3]. Third, specific antagonists of benzodiazepines (flu-
mazenil) and opioids (naloxone) are available, though no
antagonist was required in the present study.
In addition, the incidence of cardiopulmonary compli-
cations was increased when propofol alone titrated to
deep sedation [20-22]. However, despite numerous pub-
lications describing propofol use in endoscopy, there are
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complications of BPS targeted to deep sedation.
A recent prospective study by Lee et al. [5], in which
BPS was targeted to moderate sedation for advanced
endoscopic procedures, stated that the incidence of car-
diopulmonary complications was 7.2% (15/206) which
was lower than in the present study (10.8%, 28/260).
Though not directly compare, it seems that BPS tar-
geted to deep sedation might have higher cardiopulmon-
ary complications than titrated to moderate sedation.
Further direct compared study of this issue is warranted.
Interestingly, a recent study by Agostoni et al. [23]
showed that deep sedation was achieved with propofol
monotherapy with a target controlled infusion (TCI) and
the incidence of adverse events was very low, only 5.88%
in combined endoscopic procedures. The TCI technique
decreasing the amount of infused drugs might be the
reason. Direct compared study between BPS and TCI
technique is warranted.
Furthermore, hypoxemia (SpO2 <90%) is one of the
major cardiopulmonary complications of propofol based
sedation. Coté et al. [24] stated that despite supplemen-
tal oxygen by nasal cannula (2 L/min), when most of the
patients (87.2%) met the criteria for deep sedation dur-
ing advanced endoscopic procedures, hypoxemia oc-
curred in 12.8%, which was much higher than the
present study (2.6%). Preoxygenation with intranasal
oxygen (6 L/min) providing to all patients in the present
study might be the key factor of the difference.
A recent retrospective study found that under supple-
mental oxygen (4 L/min) through a nasal cannula, hyp-
oxemia was only 0.6% during colonoscopy in deeply
sedated patients [12]. Similarly, under 4 L/min intranasal
oxygen supplement, hypoxemia was not happened when
BPS titrated to moderate sedation for colonoscopy [3].
In addition, at the emergency department, Deitch et al.
reported that compared with compressed air, high-flow
oxygen 15 L per minute by a non-rebreathed mask [25],
but not nasal cannula oxygen at 2 L/min [26], reduces
the frequency of hypoxia during propofol sedation in
adults.
Thus, it suggests that intranasal preoxygenation with
high-flow oxygen 4 to 6 L per minute should be routinely
administered to patient undergoing propofol based sed-
ation targeted to deep sedation for diagnostic endoscopy.
However, supplemental oxygen can delay the occur-
rence of hypoxemia, provide a false sense of security,
and thus delay in diagnosis of respiratory depression and
airway obstruction. Therefore, it is recommended that
monitoring of ventilatory function should also include
close patient observation as in the present study.
The other important finding in this study was the high
patient overall satisfaction with the procedure. While
discharge for home, the VAS score of overall satisfactionwith the procedure was up to 9.43 in the alfentanil
group and 9.49 in the fentanyl group. Re-assessed
24 hours after the procedure again confirmed a high
level of patient satisfaction; the 10 point scale was
up to 9.76 in the alfentanil group and 9.69 in the fen-
tanyl group.
Deep sedation, causing the patient to be more com-
fortable, which was chosen in the present study, might
be the key factor. Actually, in Van Natta’s study, propofol
alone titrated to deep sedation had higher patient satis-
faction than propofol in combination with opioids and
benzodiazepines targeted to moderate sedation for col-
onoscopy, though no statistical significance was found
[3].
Though at present, there is no evidence supporting
that deep sedation might increase patient satisfaction;
additional study of this issue is warranted, especially
whether there is any difference between deep and mod-
erate sedation of BPS. Deep sedation might also achieve
better colon cancer discovery rate [27,28] and higher
level of endoscopist satisfaction [29].
Moreover, sedation technique might also influence the
patient overall satisfaction. Fanti et al. [30] reported that
patient-controlled analgesia targeted to moderate sed-
ation also achieved a high patient overall satisfaction up
to 9.11 VAS score. Further direct compared study
among different sedation techniques is necessary.
Some would argue whether deep sedation is really de-
sirable for healthy patients with diagnostic endoscopic
procedure. Internationally, sedation for colonoscopy var-
ied widely and nearly 30% colonoscopic procedure
received deep sedation [31]. In Taiwan, most of patients
and endoscopists favored deep sedation for the endo-
scopic procedures despite greater use of resource, moni-
toring and anesthetist [12,13]. Further worldwide
observation is warranted.
Furthermore, the mean total procedure time was
15 minutes in the present study. It appeared rather short
for EGD and colonoscopy and in the light of the recom-
mended 6 minutes withdrawal time. A skillful gastro-
enterologist with more than 30,000 endoscopic and
15 years experiences was involved in the study might be
the key reason of the short total procedure time. The mean
withdrawal time was 3.94 minutes in the present study.
With regard to the individual patient's anesthetic
costs, including all the anesthetic drugs consumed only,
showed a significant difference between groups. Since
the doses of midazolam and propofol are not different
between groups, the cost of alfentanil and fentanyl is the
key factor of the marked difference. Actually, due to no
generic product of alfentanil available at present time,
alfentanil 0.5 mg is about 11 times expensive than fen-
tanyl 0.05 mg, which is not offset by other costs such as
decreased operation time, shorter recovery time or
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Therefore, the use of alfentanil, added about US$ 4 per
patient to the procedure costs, could be a significant in-
stitutional financial issue.
Moreover, since BPS is administrated safely by non-
anesthetists in many countries, and there is no evidence
that the very costly presence of an anesthetist improves
the patient safety. Non-anesthetist delivered sedation
should become dominant in the world. However, it is
surprising that anesthesia professional-delivered sedation
for EGD and colonoscopy has become more common in
the United States. From 2003 to 2007, the involvement
of anesthesiologists in colonoscopy increased from 9 to
25%, and this might be up to more than 50% by 2015
[32]. Further observation is warranted.
There are limitations of our study. First, this study was
performed in a center with only one gastroenterologist
and anesthesiologist, and followed up by an independent
research nurse. Therefore, the results are difficult to
generalize. Multiple-center clinical trial might solve this
limitation.
In addition, individual differences in clinical assess-
ment and management may exist among anesthesiolo-
gists, gastroenterologists and also research nurses,
resulting in information bias and failing to reject the null
hypothesis of the study. Thus, individual difference
would be avoided in the present study. Second, the po-
tency ratio for fentanyl:alfentanil of 10:1 was chosen be-
cause of the convenient to calculate in a clinical setting.
However, this ratio is not equipotent. According to
Stanski et al., alfentanil is five to six times less potent
than fentanyl [33]. Moreover, the opioid dosage may also
have been influenced by the amount of propofol admi-
nistered to maintain a constant level of sedation. Be-
cause there is no difference in total propofol
consumption and also the procedure time between the
groups, it suggests that the convenient ratio is adequate
in the present study.Conclusion
In conclusion, the findings of the present sedation regi-
mens demonstrate that small doses of alfentanil and fen-
tanyl are equally effective adjuncts to BPS titrated to
deep sedation for EGD and colonoscopy in health exam-
ination patients. No difference in the propofol consump-
tion, awake time from sedation, recovery time, sedation-
related cardiopulmonary complications and satisfaction
score from patients was found between the two groups.
The only practical difference appears to be the cost be-
cause of the great difference in price between alfentanil
and fentanyl. This evaluation of sedation regimens may
be useful for the future development of new BPS proto-
cols to reduce the cost to a minimum.Appendix
24-hour telephone questionnaire
Q1: On a scale of 1–10, how would you rate your
procedure?
Q2: How was the sedation for your procedure? Excel-
lent Good Fair Poor
Q3: Do you think you needed any adjustment of your
sedation?
Needed more Just right Needed less
Q4: Do you remember the start of the procedure? Yes
No
Q5: Do you remember being awake during the proced-
ure? Yes No
Q6: Do you remember the end of the procedure when
the instrument was removed? Yes No
Q7: Do you think that the rest of your day was
impaired by the sedation?
None Mild Moderate Severe
Q8. Did you require additional sleep during the day-
time after the procedure?
No Yes Time (hour) ______
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